OBJECTIVE: The aim of the study was to identify risk factors associated with medical errors and iatrogenic injuries during an initial course of cancer-directed treatment. METHODS: In this retrospective cohort study of 400 patients 18 years or older undergoing an initial course of treatment for breast, colorectal, or lung cancer at a comprehensive cancer center, we abstracted patient, disease, and treatment-related variables from the electronic medical record. We examined adverse events (AEs) and preventable AEs by risk factor using the χ2 or Fisher exact tests. We estimated the association between risk factors and the relative risk of an additional AE or preventable AE in multivariable negative binomial regression models with backwards selection (P < 0.1). RESULTS: There were 304 AEs affecting 136 patients (34%) and 97 preventable AEs affecting 53 patients (13%). In multivariable analyses, AEs were overrepresented in those with lung cancer compared with patients with breast cancer (incident rate ratio = 1.9, 95% confidence interval = 1.1-3.2). Nonwhite race (1.6, 1.0-2.6), Hispanic or Latino ethnicity (2.0, 0.9-4.1), advanced disease (1.7, 1.1-2.6), use of each additional class of high-risk nonchemotherapy medication (1.6, 1.3-1.9), and chemotherapy (2.1, 1.3-3.3) were all associated with risk of an additional AE. Preventable AEs were associated with lung cancer (7.4, 2.4-23.2), Hispanic or Latino ethnicity (5.5, 1.7-17.9), and high-risk nonchemotherapy medications (1.5, 1.2-2.0). CONCLUSIONS: Risk factors for AEs among patients with cancer reflected patients' underlying disease, cancer-directed therapy, and high-risk noncancer medications. The association of AEs with ethnicity merits further research. Risk factor models could be used prospectively to identify patients with cancer at increased risk of harm.
OBJECTIVE: The aim of the study was to identify risk factors associated with medical errors and iatrogenic injuries during an initial course of cancer-directed treatment. METHODS: In this retrospective cohort study of 400 patients 18 years or older undergoing an initial course of treatment for breast, colorectal, or lung cancer at a comprehensive cancer center, we abstracted patient, disease, and treatment-related variables from the electronic medical record. We examined adverse events (AEs) and preventable AEs by risk factor using the χ2 or Fisher exact tests. We estimated the association between risk factors and the relative risk of an additional AE or preventable AE in multivariable negative binomial regression models with backwards selection (P < 0.1). RESULTS: There were 304 AEs affecting 136 patients (34%) and 97 preventable AEs affecting 53 patients (13%). In multivariable analyses, AEs were overrepresented in those with lung cancer compared with patients with breast cancer (incident rate ratio = 1.9, 95% confidence interval = 1.1-3.2). Nonwhite race (1.6, 1.0-2.6), Hispanic or Latino ethnicity (2.0, 0.9-4.1), advanced disease (1.7, 1.1-2.6), use of each additional class of high-risk nonchemotherapy medication (1.6, 1.3-1.9), and chemotherapy (2.1, 1.3-3.3) were all associated with risk of an additional AE. Preventable AEs were associated with lung cancer (7.4, 2.4-23.2), Hispanic or Latino ethnicity (5.5, 1.7-17.9), and high-risk nonchemotherapy medications (1.5, 1.2-2.0). CONCLUSIONS: Risk factors for AEs among patients with cancer reflected patients' underlying disease, cancer-directed therapy, and high-risk noncancer medications. The association of AEs with ethnicity merits further research. Risk factor models could be used prospectively to identify patients with cancer at increased risk of harm.
Authors: Allison Lipitz-Snyderman; David Classen; David Pfister; Aileen Killen; Coral L Atoria; Elizabeth Fortier; Andrew S Epstein; Christopher Anderson; Saul N Weingart Journal: J Oncol Pract Date: 2017-01-17 Impact factor: 3.840
Authors: D W Bates; D J Cullen; N Laird; L A Petersen; S D Small; D Servi; G Laffel; B J Sweitzer; B F Shea; R Hallisey Journal: JAMA Date: 1995-07-05 Impact factor: 56.272
Authors: E J Thomas; D M Studdert; H R Burstin; E J Orav; T Zeena; E J Williams; K M Howard; P C Weiler; T A Brennan Journal: Med Care Date: 2000-03 Impact factor: 2.983
Authors: Allison Lipitz-Snyderman; Saul N Weingart; Christopher Anderson; Andrew S Epstein; Aileen Killen; David Classen; Camelia S Sima; Elizabeth Fortier; Coral L Atoria; David Pfister; Allison Lipitz-Snyderman; Saul N Weingart; Christopher Anderson; Andrew S Epstein; Aileen Killen; David Classen; Camelia S Sima; Elizabeth Fortier; Coral L Atoria; David Pfister Journal: J Oncol Pract Date: 2016-02 Impact factor: 3.840
Authors: Marie Louise Tørring; Morten Frydenberg; William Hamilton; Rikke P Hansen; Marianne D Lautrup; Peter Vedsted Journal: J Clin Epidemiol Date: 2012-03-27 Impact factor: 6.437
Authors: Terry S Field; Jerry H Gurwitz; Leslie R Harrold; Jeffrey Rothschild; Kristin R DeBellis; Andrew C Seger; Jill C Auger; Leslie A Garber; Cynthia Cadoret; Leslie S Fish; Lawrence D Garber; Michael Kelleher; David W Bates Journal: J Am Geriatr Soc Date: 2004-08 Impact factor: 5.562
Authors: T A Brennan; L L Leape; N M Laird; L Hebert; A R Localio; A G Lawthers; J P Newhouse; P C Weiler; H H Hiatt Journal: N Engl J Med Date: 1991-02-07 Impact factor: 91.245
Authors: B Schuell; T Gruenberger; G V Kornek; N Dworan; D Depisch; F Lang; B Schneeweiss; W Scheithauer Journal: Br J Cancer Date: 2005-10-03 Impact factor: 7.640